Literature DB >> 31939073

Luspatercept: First Approval.

Anthony Markham1.   

Abstract

Luspatercept (REBLOZYL®) is an erythroid maturation agent developed by Acceleron Pharma and Celgene Corporation for the treatment of anaemia associated with myelodysplastic syndromes, myelofibrosis and beta-thalassaemia. Based primarily on the results of the phase III BELIEVE trial, subcutaneous luspatercept was recently approved in the USA for the treatment of anaemia associated with beta-thalassaemia. This article summarizes the milestones in the development of luspatercept leading to this first approval.

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 31939073     DOI： 10.1007/s40265-019-01251-5

Source DB:  PubMed          Journal:  Drugs        ISSN： 0012-6667            Impact factor:   9.546


  4 in total

1.  Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study.

Authors:  Uwe Platzbecker; Ulrich Germing; Katharina S Götze; Philipp Kiewe; Karin Mayer; Jörg Chromik; Markus Radsak; Thomas Wolff; Xiaosha Zhang; Abderrahmane Laadem; Matthew L Sherman; Kenneth M Attie; Aristoteles Giagounidis
Journal:  Lancet Oncol       Date:  2017-09-01       Impact factor: 41.316

2.  Luspatercept improves hemoglobin levels and blood transfusion requirements in a study of patients with β-thalassemia.

Authors:  Antonio Piga; Silverio Perrotta; Maria Rita Gamberini; Ersi Voskaridou; Angela Melpignano; Aldo Filosa; Vincenzo Caruso; Antonello Pietrangelo; Filomena Longo; Immacolata Tartaglione; Caterina Borgna-Pignatti; Xiaosha Zhang; Abderrahmane Laadem; Matthew L Sherman; Kenneth M Attie
Journal:  Blood       Date:  2019-01-07       Impact factor: 22.113

Review 3.  Luspatercept for the treatment of anemia in myelodysplastic syndromes and primary myelofibrosis.

Authors:  Pierre Fenaux; Jean Jacques Kiladjian; Uwe Platzbecker
Journal:  Blood       Date:  2019-01-02       Impact factor: 22.113

4.  Transforming growth factor-β superfamily ligand trap ACE-536 corrects anemia by promoting late-stage erythropoiesis.

Authors:  Rajasekhar N V S Suragani; Samuel M Cadena; Sharon M Cawley; Dianne Sako; Dianne Mitchell; Robert Li; Monique V Davies; Mark J Alexander; Matthew Devine; Kenneth S Loveday; Kathryn W Underwood; Asya V Grinberg; John D Quisel; Rajesh Chopra; R Scott Pearsall; Jasbir Seehra; Ravindra Kumar
Journal:  Nat Med       Date:  2014-03-23       Impact factor: 53.440
  4 in total
  2 in total

1.  Development of luspatercept to treat ineffective erythropoiesis.

Authors:  Anne Sophie Kubasch; Pierre Fenaux; Uwe Platzbecker
Journal:  Blood Adv       Date:  2021-03-09

Review 2.  Luspatercept: A Gigantic Step in the Treatment of Transfusion-Dependent β-Thalassemia Patients-a Quick Review.

Authors:  Hadi Darvishi-Khezri; Hossein Karami
Journal:  Adv Ther       Date:  2021-03-04       Impact factor: 3.845
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.